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SUMMARY
The polypyrimidine tract binding protein (PTB) is an 
important regulator of alternative splicing. PTB-
regulated splicing of α-tropomyosin is enhanced by 
Raver1, a protein with four PTB-Raver1 Interacting 
motifs (PRIs) that bind to the helical face of the 
second RNA recognition motif (RRM2) in PTB. We 
present the crystal structures of RRM2 in complex 
with PRI3 and PRI4 from Raver1, which — along with 
structure-based mutagenesis — reveal the molecular 
basis of their differential binding. High-affinity binding 
by Raver1 PRI3 involves shape-matched apolar 
contacts complemented by specific hydrogen bonds, 
a new variant of an established mode of peptide-RRM 
interaction. Our results refine the sequence of the PRI 
motif and place important structural constraints on 
functional models of PTB-Raver1 interactions.  Our 
analysis indicates that the observed Raver1-PTB 
interaction is a general  mode of binding that applies to 
Raver1 complexes with PTB paralogues such as nPTB 
and to complexes of Raver2 with PTB.
INTRODUCTION
Alternative splicing in metazoans produces multiple mRNA 
transcripts from a single gene and is a powerful mechanism for 
amplifying proteome complexity. Over 95% of human multi-exon 
genes have multiple splice isoforms (Nilsen and Graveley, 2010). 
The process of pre-mRNA splicing involves the controlled 
inclusion or exclusion of specific exons and is regulated by cis-
acting enhancer or silencer sequences found either within the 
exon or within the flanking introns (Matlin et al., 2005). The 
temporal and spatial control of splicing is also determined by 
various positive and negative protein co-factors, which are 
activated by developmental or differentiation-specific cues.
One of the most intensively studied regulators of alternative 
splicing is the polypyrimidine tract binding protein (PTB). PTB is a 
versatile protein. In addition to its nuclear splicing activity PTB is 
also found in the cytoplasm where it has roles in the stabilisation 
and localization of mRNA (Ghetti et al., 1992; Cote et al., 1999; 
Tillmar et al., 2002); it is also recruited to stimulate translation 
initiation driven by internal ribosome entry sites (IRES) from 
cellular and viral mRNAs (Sawicka et al., 2008).
PTB is expressed in a variety of tissues (Patton et al., 1991) 
and represses many muscle and neuron-specific exons, tissues in 
which PTB levels are low (Xue et al., 2009; Llorian et al., 2010). It 
has a number of tissue-specific paralogues in neurons (nPTB) 
(Markovtsov et al., 2000; Polydorides et al., 2000), hematopoietic 
cells (ROD1) (Yamamoto et al., 1999) and smooth muscle cells 
(smPTB) (Gooding et al., 2003) which, with at least 50% amino 
acid sequence identity, are closely related to the prototypical 
protein. These paralogues appear to supplant or modulate the 
program of splicing activity of PTB in the tissues where they occur 
(Boutz et al., 2007; Makeyev et al., 2007). 
Though best known as a negative regulator of splicing, acting 
to exclude specific exons, PTB has recently been found to 
determine exon inclusion in some cases (Xue et al., 2009; Llorian 
et al., 2010). In common with a number of other splicing 
regulators, its activity appears to be determined by the location at 
which it binds to the RNA relative to the regulated exon (Witten 
and Ule, 2011).
Several different mechanisms have been proposed for the 
repressive splicing activity of PTB, including direct binding to pre-
mRNA in order to block binding of U2AF65 — a component of the 
spliceosome — to the polypyrimidine tract (Lin and Patton, 1995; 
Singh et al., 1995) or oligomeric assembly across exons to mask 
splice sites (Wagner and Garcia-Blanco, 2001). In other cases, 
PTB does not directly block splicing factor binding, but rather the 
formation of splicing complexes across exons or introns; these 
indirect mechanisms appear to result from the ability of PTB to re-
model pre-mRNA by bringing distal regions of RNA into close 
proximity and so inducing looping (Chou et al., 2000; Izquierdo et 
al., 2005; Cherny et al., 2010) or, as has been shown more 
recently, by bridging non-productive association of pre-mRNA with 
stem-loop IV of U1 snRNA (Sharma et al., 2008; Sharma et al., 
2011). These mechanisms may all operate, depending on the 
particular pre-mRNA being spliced, though part of the observed 
variety is likely a reflection of the technical difficulty of studying 
splicing at the molecular level. 
Nevertheless, it is clear that PTB binds to both RNA and 
proteins during splicing. The protein binds pyrimidine-rich motifs 
within RNA (e.g. UCUU, CUCUCU), which are found in regulatory 
elements (Pérez et al., 1997; Ray et al., 2009) that may be 
structured (Clerte and Hall, 2009; Kafasla et al., 2009). PTB binds 
RNA via β-sheet surfaces on the four RNA recognition motif 
domains (RRMs; Fig. 1A) (Conte et al., 2000; Simpson et al., 
2004; Oberstrass et al., 2005) that are arrayed in an elongated 
conformation (Petoukhov et al., 2006). This arrangement allows 
multi-point contacts with RNA targets that can re-model or 
stabilise RNA structures containing pyrimidine-rich motifs and 
offers a plausible basis for models of PTB-mediated repression 
that invoke looping of pre-mRNA (Oberstrass et al., 2005; Cherny 
et al., 2010; Lamichhane et al., 2010) or contacts between pre-
mRNA and U1 snRNA (Sharma et al., 2011). 
Splicing regulation by PTB or its paralogues also appears to 
involve interactions with other regulatory proteins including 
Nova-1 and Nova-2 (Polydorides et al., 2000), Raver1 (Gromak et 
al., 2003) and MRG15 (Luco et al., 2010). The best characterised 
of these is the PTB-Raver1 interaction which modulates splicing 
of α-tropomyosin (Tpm1). PTB acts to exclude the mutually 
exclusive exon 3 of Tpm1 in smooth muscle cells but not in other 
cells where PTB is expressed (Gooding et al., 1998). 
Overexpression of PTB has little effect on this splicing event, 
suggesting that it is not limiting. However, overexpression of 
Raver1 (Hüttelmaier et al., 2001) causes a large increase in exon 
skipping (Gromak et al., 2003).
Raver1, which is expressed in most tissue types, can be found 
not only in the nucleus but also the cytoplasm, where it interacts 
with cytoskeletal proteins (Hüttelmaier et al., 2001). The protein 
has three N-terminal RRMs — although only RRM1 has 
demonstrable, albeit weak, RNA-binding activity (Lee et al., 2009) 
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— and an extended Pro-rich C-
terminus that contains 4 conserved 
PTB interacting motifs (PRIs) with the 
consensus sequence [S/G][I/L]LGxxP 
(Rideau et al., 2006) (Fig. 1A). These 
motifs, which are essential for Raver1 
function, bind exclusively to the α-
helical side of the PTB RRM2 
opposite to the RNA-binding surface, 
a mode of interaction that permits 
formation of ternary PTB-RNA-Raver1 
complexes. The initial analysis of 
PTB-Raver1 interactions showed that 
only PRIs 1 and 3 bind with relatively 
high affinity (Rideau et al., 2006). 
Raver2, which is a related protein of 
unknown function, has a similar 
domain structure to Raver1: three N-
terminal RRMs and a Pro-rich C-
terminus (Fig. 1A) (Kleinhenz et al., 
2005). Although the C-terminus is the 
least well-conserved portion between 
the two proteins, Raver2 contains two 
PRI motifs that are very similar to the 
PRI1 and PRI3 motifs found in Raver1 
and have been shown also to mediate 
binding to PTB (Henneberg et al., 
2010).
The first structural analysis of the 
interaction of peptides containing 
Raver1 PRI sequences with PTB only 
yielded an NMR-restrained docking 
model since the affinity of purified 
PTB RRM2 for synthetic PRI3 
peptides was too low for a full 
structure determination (Rideau et al., 
2006). Although it provided valuable 
insights, this model is not precise 
enough to allow full dissection of the 
structural basis of binding of Raver1 
PRIs to PTB. By fusing Raver1 PRIs 
as N-terminal extensions to PTB 
RRM2, we have now obtained crystal 
structures of PTB RRM2 complexed with Raver1 PRI3 and PRI4, 
which are high-affinity and low-affinity motifs respectively. In 
combination with mutagenesis, binding and splicing assays, these 
new structural data reveal a mode of PTB-Raver1 interaction that 
is applicable to PTB paralogues and other PRI-containing proteins 
and that places useful constraints on models of the joint action of 
PTB and Raver proteins.
RESULTS
Construct.design.and.characterization
To determine the structure of a PTB-Raver1 complex, we 
overcame the weak binding of short Raver1 peptides to PTB 
(Rideau et al., 2006) by fusing the PRI3 sequence as an N-
terminal extension of PTB RRM2 to increase the local 
concentration artificially, a strategy that has worked for other 
protein-peptide complexes (Candel et al., 2007). The PTB-Raver1 
docking model indicated that a linker of at least 20 amino acids 
would be required to join the C-terminal end of the bound PRI3 
peptide to the N-terminus of RRM2 (Rideau et al., 2006). The first 
chimeric construct (PRI3-RRM2) was therefore designed to 
contain the 12-residue PRI3 sequence (PGVSLLGAPPKD — the 
conserved core residues, which we number 1-7, are underlined) 
followed by residues 156-285 of PTB RRM2. Residues 156-179 
are from the polypeptide that links RRM1 to RRM2 in the full-
length protein; residues 180-285 correspond to the structured 
RRM2 domain (Simpson et al., 2004) (see Experimental 
Procedures). The PRI3 sequence used in the chimera contains a 
Glu to Ala mutation at position 5 in the core sequence, a carry-
over from the previous NMR analysis, but this substitution does 
not affect binding (Rideau et al., 2006).
The expression levels in E. coli and the solubility of the PRI3-
RRM2 chimera are much higher than for constructs just 
containing RRM2 from PTB. PRI3-RRM2 is soluble to at least 
25 mg/ml, whereas recombinant RRM2 precipitates above 6 mg/
ml (Simpson et al., 2004). Although NMR analyses and size-
exclusion chromatography suggested that PRI3-RRM2 exhibited 
concentration-dependent oligomerisation (not shown) the fusion 
protein produced diffraction-quality crystals. We therefore used 
the same strategy to fuse PRIs 1, 2 and 4 of Raver1 and the PRI 
from hnRNP-L and matrin-3 to PTB RRM2 (Fig. 3D). All these 
constructs had enhanced solubility similar to PRI3-RRM2, but 
on ly the construct conta in ing the low-aff in i ty PRI4 
(SSEGLLGLGPGP) also crystallised.
Crystal.structures.of.PRI36.and.PRI46RRM2
PRI3-RRM2 and PRI4-RRM2 crystals diffracted X-rays to 1.4 Å 
and 1.55 Å respectively. Diffraction data were phased by 
molecular replacement using the NMR structure of PTB RRM2 
(Simpson et al., 2004) as a search model. In each case, only 
central portions of the PRI sequences were revealed by difference 
electron density maps (PRI3: VSLLGAPP; PRI4: SEGLLGL) (Fig. 
S1); there was no density for the linker peptides connecting these 
to the RRM2 domain so these were not incorporated into the 
atomic models. Final models for PRI3-RRM2 and PRI4-RRM2 
were refined to Rfree values of 23.1% and 22.1% respectively (see 
Table 1 for full statistics).
The crystals of PRI3-RRM2 and PRI4-RRM2 have 2 complexes 
in the asymmetric unit, which have almost identical structures: 
e.g. for PRI3-RRM2 the all atom RMSD is 0.22 Å (Fig. S1B). 
Comparison of the RRM2 structures in each complex with the 
solution structures of PTB RRM2 (RMSD=1.0 Å over Cα atoms) 
(Simpson et al., 2004; Oberstrass et al., 2005) reveals no 
significant structural changes upon peptide binding. 
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Figure.1..Structures.of.Raver1.PRIs.bound.to.PTB.RRM2.(
(A) Schematic diagrams of PTB, Raver1 and Raver2 showing locations of RRMs and PRIs. Residue numbers 
are indicated above each protein. 
(B) Comparison of the crystal structure of Raver1 PRI3 (green) bound to RRM2 (tan) with the NMR-restrained 
docking model of the PRI3 peptide (grey). The structures are shown schematically as cartoon representations; 
the N- and C-termini of the peptides are coloured blue and red respectively. Close up views of the interactions 
of (C and D) Raver1 PRI3 and Raver1 PRI4 with PTB RRM2. The Van der Waals surface of the RRM is 
depicted as a semi-transparent skin. All structural figures were created using PyMOL (Delano, 2002).
Conformations.of.PRI3.and.PRI4.bound.to.PTB.RRM2
The crystal structures of PRI3 and PRI4 from Raver1 in complex 
with PTB RRM2 are consistent with many of the features found in 
previous work: the peptides bind to the dorsal helical face of the 
RRM domain and in the same orientation as determined by NMR 
methods (Fig. 1B) (Rideau et al., 2006). However, they provide a 
much more detailed information on the peptide-RRM interaction 
and reveal previously undetected features of the bound peptide. 
Strikingly, although our NMR-restrained docking model assumed 
an extended conformation of the bound peptide, the core peptides 
of PRI3 and PRI4 in the crystal structures adopt S-shaped 
conformations that wrap around the peptide binding surface on 
RRM2, which is formed by the α1 and α2 helices plus the β1- α1 
and α2- β4 loops (Fig. 1C,D). Our earlier NMR docking model for 
the Raver1-RRM2 complex was derived from eleven 
intermolecular NOEs involving methyl groups and aromatic rings 
(Rideau et al., 2006). All NOEs to Raver methyl groups are 
satisfied by the crystal structure presented here, with the 
exception of the A503, which is slightly farther away from the 
RRM domain than in solution (Figure S2). This small difference is 
not unexpected, as extensive conformational exchange was 
observed in NMR spectra of bound Raver1, and likely reflects 
some averaging in this region in solution.
There is an extensive bipartite hydrophobic interface between 
the peptides and RRM2: the pair of Leu side chains at positions 2 
and 3 in the motif both project into a shallow apolar depression 
between the two helices on the dorsal face of RRM2, while 
downstream residues of the PRIs are packed around the side 
chains of Tyr 247 and Tyr 193, though in very different 
conformations for the two peptides (Fig. 2). For PRI3 the four-
residue sequence 3LGAP6 wraps around Tyr 247 (Fig. 2B), while 
in PRI4 a different backbone conformation means that just three 
residues, 3LGL5, are in contact with the tyrosine (Fig. 2D). 
Moreover, although in PRI3 Pro 6 and Pro 7 both contact the side 
chains of Tyr 247 and Tyr 193, the equivalent residues in PRI4 
(Gly 6 and Pro 7) are not visible in the electron density map, 
presumably due to disorder; this difference is likely to contribute 
to the lower affinity of PRI4. The occlusion of hydrophobic 
features on the surface of RRM2 by the Raver1 peptide probably 
accounts for the enhanced solubility of the chimeric PRI-RRM2 
proteins.
The observed hydrophobic contacts made by the Leu side-
chains at positions 2 and 3 in the PRI explain why substitution of 
either residue by smaller apolar residues is detrimental to binding 
(Rideau et al., 2006). However, it is not clear why a Leu-to-Ile 
substitution at position 2 in PRI3 has no effect, whereas the same 
substitution at position 3 effectively abrogates binding of the 
Raver1 PRI, especially since Leu 3 binds within a shallower 
depression. Perhaps the branching at the Cβ in Ile introduces a 
steric clash that distorts nearby hydrogen 
bonds between the Raver1 PRI3 and PTB 
RRM2.
In addition to the apolar contacts, there 
are specific hydrogen bond interactions 
that contribute to PRI binding to PTB 
RRM2. These show clear differences 
between PRI3 and PRI4, which probably 
also contribute to the affinity differences 
between these two motifs. In PRI3 (core 
sequence: SLLGAPP) Leu 2 and Leu 3 
both project in the same direction into the 
binding pocket on PTB RRM2 because of 
a pinched backbone conformation that is 
stabilised by an internal hydrogen bond 
from the side-chain hydroxyl of Ser 1 to 
the backbone amide of Gly 4 (Fig. 2A). In 
this conformation the peptide is able to 
make four hydrogen bonds to PTB RRM2.
In contrast, PRI4 (core sequence: 
GLLGLGP) makes only 3 intermolecular 
hydrogen bonds. The absence of Ser at 
position 1 eliminates the intra-peptide 
hydrogen bond and results in a more open 
backbone conformation. The loss of this 
internal interaction allows the peptide 
bond between Leu 3 and Gly 4 to flip with 
respect to PRI3, a conformational change 
that eliminates a hydrogen bond to RRM2 
(from the carbonyl group of Gly 4 –Fig. 
2C), which likely reduces the affinity of this 
motif, although the peptide flip is also 
needed to allow the 3LGL5 sequence to 
wrap around Tyr 247.
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Figure.2..Detailed.structural.comparison.of.Raver.1.PRIs.3.and.4.bound.to.PTB.RRM2.(
(A, B) Close up views of PRI3 bound to RRM2. Intramolecular hydrogen bonds are shown as orange 
dashes; intermolecular hydrogen bonds are yellow. (C, D) Equivalent views of PRI4 bound to RRM2. 
Table. 1.. Data. collection,. Data. processing. and. reTinement.
statistics.for.crystal.structures.of.PRI36RRM2.and.PRI46RRM2..
PRI3-RRM2 PRI4-RRM2
Refinement Statistics
Space Group C2 C2
   a, b, c (Å) 74.23, 60.60, 60.84 74.48, 60.38, 61.06
   α, β, γ (°) 90, 90, 107.51 90, 90, 107.86
Resolution Range (Å) 30.32-1.40(1.48-1.40)
35.49-1.55 
(1.63-1.55)
Reflections 50129 36156
Multiplicity 5.6 (5.3) 2.4 (2.4)
Completeness (%) 98.9 (96.1) 96.9 (96.5)
I/σI 15.4 (5.3) 10.2 (3.0)
Rmerge (%) 6.4 (35.4) 5.5 (35.8)
Refinement Statistics
R
calc
 (%) 22.3 21.6
R
free
 (%) 23.1 22.1
Non-hydrogen atoms 1741 1723
Waters 191 132
rms bond lengths (Å) 0.005 0.005
rms bond angles (°) 1.32 1.31
Ramachandran 
(% favoured/allowed) 98.0/1.4 97.7/2.3
PDB ID 3zzy 3zzz
Values in parentheses are for the highest resolution shell. PDB, Protein 
Data Bank; rms, root-mean-square.
Dissecting.the.structural.basis.of.differential.PRI.afTinity
Previous work established that PRIs 1 and 3 bind with 
significantly higher affinity than PRIs 2 and 4 (Rideau et al., 
2006). The new structural information suggests that the Leu 2-
Leu 3 dipeptide found in both motifs is not sufficient for high-
affinity binding; instead variations in amino acids at positions 1, 5 
and 6 appear to be crucial. To explore this idea we introduced 
mutations into PRI3 and PRI4 peptides (fused to MS2 proteins at 
their C-termini) and tested their effect on binding affinity in pull-
down assays (Experimental Procedures).
Pro 6 of PRI3, which is conserved in the other high affinity 
motif, PRI1, makes apolar contacts with Tyr 247 and Tyr 193 that 
are likely to contribute significantly to binding affinity. This was 
confirmed by mutagenesis: although conservative mutations of 
Pro 6 to Ala or Val, both of which retain the apolar character of the 
side chain, only very slightly reduced the affinity of PRI3 for PTB 
RRM2, substitution by a polar Ser reduced binding 7-fold (Fig. 
3A). Thus, the presence of a polar residue at position 6 within the 
PRI is detrimental to binding, a result that is consistent with the 
low-affinity of Raver1 PRI2 and the PRI from hnRNP L, which 
have Ser and His at this position respectively (Rideau et al., 2006) 
(Fig. 3D).
To further explore the peptide features that affect binding to 
PTB, we performed experiments to examine what changes would 
be necessary to enhance the binding affinity of Raver1 PRI4. The 
structure shows that the presence of Gly 1 in PRI4 eliminates the 
internal stabilisation of the backbone of PRI3 due to the hydrogen 
bond between Ser 1 and Gly 4 (Fig. 2 A & C). However, this 
interaction seems to have little effect on the affinity for RRM2 
since substitution of Gly 1 by Ser in PRI4 only increased the 
binding 1.7-fold (Fig. 3B), consistent with the observation that Gly 
occurs at position 1 in the high affinity PRI1 sequence (Fig. 3D). 
In contrast, there was a stronger 4  -fold enhancement of binding 
when the double mutation Leu5Ala/Gly6Pro was used to convert 
the 3LGLGP7 sequence in PRI4 to the 3LGAPP7 found in our 
modified version of the high-affinity PRI3 and in PRI1 (Fig. 3B). 
Together these observations suggest that interaction of Pro 6 with 
the tyrosine pocket in PTB RRM2 is essential for a high-affinity 
interaction with PTB, while the backbone stabilisation due to Ser 1 
plays a minor supporting role. Moreover, the mutagenesis results 
help to verify the functional relevance of the structures obtained 
from our artificial chimeric constructs.
Intriguingly, the L5A/G6P substitutions in PRI4 make its core 
sequence identical to that of PRI1 (Fig. 3D) but this mutant binds 
about 10-fold less well to GST-PTB than PRI1 (Fig. 3C). This 
suggests that elements outside the conserved core motif of 
Raver1 may play a role in binding to PTB. However, although the 
20-residue peptide sequence used in the binding assays is longer 
than the 12-residue sequence incorporated into the chimeric 
constructs used for crystallisation, comparison of the flanking 
sequences (Fig. 3D) reveals no obvious patterns of conservation 
that correlate with binding. 
Interactions.of.Raver1.PRIs.with.nPTB
To identify whether the mode of binding of Raver1 PRI peptides to 
PTB is the same in other PTB paralogues, we investigated their 
binding to GST-nPTB in pull-down assays. The sequence identity 
between PTB and nPTB is over 74% (Markovtsov et al., 2000; 
Polydorides et al., 2000). Mapping of the RRM2 sequence 
differences between PTB and nPTB onto the structure reveals 
that they cluster in 2 distinct regions. One group is located on the 
upper surface of helix α2, quite separate from the PRI binding 
site, whereas a second smaller cluster occurs on the β1-α1 loop 
which, together with the adjacent α2-β4 loop, forms part of the 
Raver1 binding surface (Fig. S3A). Despite these differences, 
binding assays revealed that the relative affinities of PRIs 1-4 for 
PTB and nPTB are very similar. Thus, PRI1 and PRI3 bind 
strongly to both paralogues, while PRI2 and PRI4 have much 
weaker affinity (Fig. S3C). Furthermore, mutations designed to 
reduce or enhance the affinities of PRI3 and PRI4 for PTB RRM2 
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Figure.3..Effect.of.mutations.of.Raver1.PRIs.
on.binding.to.GST6PTB. 
(A) Pull-down assays of binding of Raver1 PRI3 
mutants to GST-PTB. Left Loading controls for 35S-
Met-labelled PRI3-MS2 fusion proteins containing 
PRI3 wt and the mutants P6V, P6S and P6A 
(Experimental Procedures). Right, Autoradiogram of 
PRI3-MS2 proteins pulled down with GST (1 µg) or 
GST-PTB (3 µg). 
(B)Pull-down assays of binding of Raver1 PRI4 
mutants to GST-PTB. Left Loading controls for 35S-
Met-labelled PRI4-MS2 fusion proteins. Right, GST 
Pull-down of PRI4 constructs with GST (5 µg) or GST-
PTB (15 µg). Although PRI4 constructs migrate as a 
doublet (as observed previously (Rideau et al., 2006)), 
both products of the in vitro transcription-translation 
reaction contain the PRI since they bind PTB with the 
same affinity. 
(C)Comparison of binding of wild-type and mutant 
Raver1 PRIs to GST-PTB. Left Loading controls. 
Right, GST Pull-down of PRI4 constructs with GST 
(2 µg ) or GST-PTB (6 µg). 
(D) PRI sequences from murine Raver1 (AAP33691), 
murine Raver2 (NP_898845), human matrin-3 
(NP_001181884) and human hnRNP-L (NM_001533). 
Sequences shown for Raver1 are the 20 amino 
peptides used in pull-down assays; the shaded box 
indicates the sequences included in PRI-RRM2 
chimeras for structural studies. Sequence similarity 
and identity within the PRI core are indicated. 
Residues in Raver1 PRIs 3 and 4 that were tested by 
mutagenesis are in boldface.
had similar effects on their binding to nPTB: the P6S mutation in 
PRI3 P6S reduced binding for nPTB, while the binding PRI4 L5A/
G6P was enhanced (compare Fig. S3C with Fig. 3). These 
observations support the contention that PTB and nPTB interact 
with Raver1 PRIs in the same way.
PTB.mutations.affect.PRI.binding.and.activity
To extend our understanding of the PTB-Raver1 interaction we 
generated PTB RRM2 mutants and tested them for binding of 
Raver1 and RNA and for their ability to regulate splicing of Tpm1.
PTB RRM2, along with the following inter-RRM linker (PTB 2L), 
was previously shown to be fully active as a splicing repressor 
domain when fused to MS2 coat protein and tethered to Tpm1 
RNA by an MS2 binding site, which replaced the natural 
downstream PTB binding site (Robinson and Smith, 2006). We 
therefore used this tethered repressor domain assay to test the 
effects of mutations designed to target the PTB-Raver1 
interaction. Cotransfection of the splicing reporter construct with 
an MS2 expression vector had no effect on the low basal level of 
exon skipping (Fig. 4A lanes 1,2), while transfection of wild type 
PTB 2L-MS2 led to 61% exon skipping (lane 3). Mutations of 
Tyr 193, Leu 241 and Gln 244 had no effect (data not shown). 
However, mutation of Tyr 247 to Gln reduced activity by a third 
(Fig. 4A, lane 4). This reduction in activity is consistent with the 
close contacts made by Tyr 247 with hydrophobic side chains in 
each of the PRIs (Fig. 2B,D). As a control, we also tested the 
effects of mutations on the RNA binding surface of RRM2 (K271A 
and K266A/Y267A/K271A), which are predicted to have no effect 
on PRI binding. Both single and triple RNA binding mutations 
severely impaired the splicing repressor activity (Fig. 4A, B). To 
confirm the specificity of the mutations, recombinant GST-PTB 
RRM2 proteins were tested for the ability to pull-down in vitro 
translated Raver1 protein (Fig. 4D) and to bind to RNA (Fig. 4C). 
As expected, the Y247Q mutant showed complete impairment of 
Raver1 interaction (Fig. 4D; compare to GST-Sxl non-specific 
control), but bound to RNA comparably to wild-type RRM2. In 
contrast, the K271A mutant was impaired for RNA binding but 
interacted with Raver1. These observations are consistent with 
the previous finding that PTB RRM2 can form a ternary complex 
with the Raver1 PRI and a short RNA oligomer (Rideau et al., 
2006), and confirm the independence of the two interacting 
surfaces of RRM2. Moreover, it is interesting to note that, given 
that RRMs 1 and 2 of PTB have been shown to interact with U1 
stem-loop 4 (Sharma et al., 2011), the strong effect of the RNA 
binding mutations in PTB 2L-MS2 on repression of Tpm1 exon 3 
(Fig. 4) may be due to impairment of binding to U1 snRNA.
DISCUSSION
In this report we present the first structural analysis of a PTB-
protein complex involved in splicing: the crystal structures of PTB 
RRM2 in complex with two peptide motifs from Raver1, the 
protein recruited to co-repress exon 3 of Tpm1. Though the 
structures contains only a single domain of PTB, this is the major 
structured portion of PTB-2L, the minimal fragment required to 
recapitulate the activity of the full-length protein in exon exclusion 
(Robinson and Smith, 2006) and, as has been shown more 
recently, inclusion (Xue et al., 2009; Llorian et al., 2010).
Analysis of the structure and RNA-binding properties of PTB 
have helped to inform ideas about how PTB works, first by 
delineating the unexpected architecture of the domains and so 
paving the way for more precise functional studies using 
structure-based mutagenesis (Conte et al., 2000; Simpson et al., 
2004; Oberstrass et al., 2005), and then by revealing modes of 
RNA binding, which led to testable suggestions of how binding of 
PTB might re-model RNA to affect splicing (Oberstrass et al., 
2005; Petoukhov et al., 2006; Lamichhane et al., 2010).
Our growing understanding of PTB-RNA interactions has 
influenced models of PTB-mediated exon repression — its best-
characterised activity. Several plausible mechanisms have 
emerged, built on the observation that PTB molecules are 
involved at multiple binding sites in pre-mRNA located within or 
near to regulated exons. Possible modes of repression include 
masking of splicing signals by direct contact (Singh et al., 1995; 
Wagner and Garcia-Blanco, 2001) or PTB-mediated looping 
(Chou et al., 2000; Oberstrass et al., 2005; Cherny et al., 2010; 
Lamichhane et al., 2010; Llorian et al., 2010); additionally or 
alternatively PTB may interfere with spliceosome assembly by 
binding to stem-loop 4 of U1 snRNA (Sharma et al., 2011). 
Less attention has been paid to the interactions that PTB 
makes with other proteins to regulate splicing (or indeed, any 
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Figure.4..Mutation.of.PTB.RRM2.RNA.and.PRI.interacting.
surfaces.impairs.activity..
(A) Effects of RRM2 mutations on an MS2-tethered splicing regulation 
assay. The Tpm1 exon 1-3-4 splicing reporter, with the PTB site 
downstream of exon 3 replaced by a pair of MS2 coat protein binding 
sites, was transfected into HeLa cells and splicing patterns analyzed by 
RT-PCR. Lane 1, reporter alone, lane 2, cotransfected with MS2 coat 
protein. Lanes 3-6 reporter cotransfected with MS2-PTB2L expression 
constructs (wt, Y247Q, K271A, K266A/Y267A/K271A, respectively). 
Percent exon skipping (± sd) is shown below each lane. 
(B) Western blots to show equivalence of expression of MS2-PTB2L 
tested in panel A (anti-FLAG). Loading control, anti-actin. 
(C) Electrophoretic mobility shift assay of 0.23.2 µM recombinant PTB 
RRM2 wild type (lanes 2-6), Y247Q (lanes 7-11); K271A. Lane 1, no 
protein. 
(D) Pull-down of in vitro translated full length Raver1 with the indicated 
GST-fusion proteins.
other PTB-mediated activity), despite observations of PTB-binding 
partners that have accumulated over the past ten years and now 
include not only Raver1 and Raver2 (Hüttelmaier et al., 2001; 
Henneberg et al., 2010), but also Nova-1/2 (Polydorides et al., 
2000) and, possibly, MRG15 (Luco et al., 2010). Clearly 
delineation of the details of PTB-protein interactions is important 
for a more complete understanding of the molecular mechanism 
of splicing regulation.
The crystal structures of PTB RRM2 in complex with Raver1 
reveals a mode of peptide binding that has been observed in 
other RRM-peptide complexes such as U2AF35/U2AF65 
(Kielkopf et al., 2001), SPF45/SF3b155 (Corsini et al., 2007) and 
eIF3b/eIF3j (Elantak et al., 2010): the peptide binds in an 
orientation that is broadly perpendicular to the two helices on the 
dorsal surface of the RRM (Fig. 5). [The REF/ICP27 complex, in 
which the peptide lies parallel to the helices, is a notable 
exception (Tunnicliffe et al., 2011) (Fig. S4)].
Nevertheless, the PTB-Raver1 complex marks an interesting 
variation on this theme. Although in the three examples of 
perpendicular binding mentioned above peptide binding is 
anchored by insertion of a Trp side-chain from the peptide into a 
deep apolar pocket between the helices on the RRM, in the 
Raver1 peptide the role of this Trp is taken by a pair of Leu side-
chains that insert into a shallower hydrophobic depression in a 
similar location on the RRM. This pair of Leu side-chains make 
important hydrophobic contacts that contribute to binding of 
Raver1 PRIs to PTB RRM2, but they are not sufficient for high-
affinity binding since this sequence feature is also found in PRIs 2 
and 4, which have lower affinity (Rideau et al., 2006). Additional 
interactions are also important for tight binding. The PRI3-RRM2 
complex reveals that these include a number of specific hydrogen 
bonds — mostly between main-chain groups — and the 
interaction of the Pro-Pro dipeptide at positions 6 and 7 in the 
motif with the Tyr pocket formed by Tyr 247 and Tyr 193 (Fig. 2B). 
Although PRI4 exhibits an alternative mode of binding, which 
inserts a hydrophobic Leu side-chain (from position 5 of the motif) 
within this Tyr pocket, this is insufficient for high-affinity binding 
(Fig. 3C). Moreover, mutagenesis experiments show that 
substitution of the Pro at position 6 in the PRI3 motif with a polar 
residue (such as Ser) is sufficient to impair binding (Fig. 3A), a 
result that accounts for the low affinity observed for the PRI2 
sequence of Raver1 (Rideau et al., 2006). The overall mix of 
interactions observed echoes similar observations from other 
structures of RRM-peptide complexes such as U2AF35/U2AF65 
(Kielkopf et al., 2001), and SPF45/SF3b155 (Corsini et al., 2007).
Given the close sequence similarity between the PRI1 and 
PRI3 motifs from Raver1, the structural and binding data 
presented here offer a plausible explanation for the high affinity of 
PRI1 and strongly suggest it binds to PTB RRM2 in the same 
way. The same can probably also be said of the two high-affinity 
PRI motifs in Raver2 which are similar to Raver1 PRI1 and PRI3 
(Henneberg et al., 2010) (Fig. 3D). 
We have also shown that despite a cluster of sequence 
differences between PTB and its neuronal paralogue near the 
Raver1-binding site on RRM2, nPTB exhibits a very similar 
pattern of variation of affinity for the Raver1 PRIs (Fig. S3). The 
Raver1 binding site is 
therefore common to both these paralogues and it will be worth 
investigating whether this function is retained by other PTB 
paralogues such as ROD1 (Yamamoto et al., 1999; Hüttelmaier et 
al., 2001) and smPTB (Gooding et al., 2003).
Furthermore the results allow us to refine the definition of what 
constitutes a high-affinity PRI sequence from [S/G][I/L]LGxxP to 
[S/G][I/L]LGxΦP, where the Φ at position 6 indicates a preference 
for a small hydrophobic residue (Pro, Val, Ala).  Using 
ScanProsite (de Castro et al., 2006) 36 human proteins can be 
identified that contain predicted high affinity PRIs conforming to 
([S/G][I/L]LGx[AVP]P, including Raver1 and 2, each of which 
contain two sites.  The nuclear matrix protein matrin-3 contains 
the motif GILGPPP, which is necessary and sufficient for 
interaction with PTB (M.C. and C.W.J.S. manuscript in 
preparation).  In addition, the 3  ´ end processing factors CSTF2 
and CSTF2T both contain the motif GLLGDAP suggesting a 
molecular basis for how PTB is able to activate some 
polyadenylation sites (Castelo-Branco et al., 2004).  Other 
potential PRI containing proteins such as the deacetylase HDAC6 
and a histone demethylase, JMJD8, hint at further interesting 
and functionally diverse targets of PTB.
The PTB-Raver1 complexes presented here place constraints 
on possible modes of co-repression by PTB and Raver1. Although 
there are four PTB-binding motifs in the C-terminal region of 
Raver1, each appears capable of only binding to a single 
molecule of PTB. The stoichiometry of PTB-Raver1 complexes 
that assemble on regulated exons could therefore be 2:1, if only 
high-affinity sites are engaged. However, it remains possible that 
low affinity sites may also contribute to binding, not least because 
tethering of Raver1 to PTB via the two high-affinity sites will 
augment the local concentration of PRIs. This would be consistent 
with the model envisaged by Cherny and colleagues (2010), on 
the basis of their observations of multiple PTB molecules binding 
in the vicinity of regulated exons in Tpm1. Against this, however, it 
is has been observed that mutation of a single PRI3 motif in 
Raver1 — and of an identical PRI in Raver2 (PRIb in Fig. 3D) 
— was sufficient to abrogate binding to PTB and PTB-mediated 
localisation to perinucleolar comparments in HeLa (Henneberg et 
al., 2010). While this may point to a 1:1 stoichiometry for PTB-
Raver1 complexes, it remains true that mutation of other high-
affinity PRIs in Raver1 or Raver2 significantly reduces binding to 
PTB (Rideau et al., 2006; Henneberg et al., 2010). The full details 
of functional PTB-Raver1 interactions have yet to be worked out. 
It is tantalising to note the similar spacing between the high-
affinity PRIs in Raver1 and Raver2 (about 135 amino acids; see 
Fig. 1A), which perhaps points to a common architecture of 
functional PTB-Raver complexes. 
EXPERIMENTAL.PROCEDURES
Plasmid.construction
For structural analysis PRI-RRM2 chimera constructs containing residues 
156-285 of PTB were generated by PCR using PTB1 cDNA as a template 
(Gil et al., 1991). The forward primer incorporated an NcoI site and 
sequences coding for 12 amino acids from the PRI sequences (from 
Raver1, hnRNP-L and matrin-3), while the reverse primer introduced a stop 
codon and downstream HindIII site. The resulting PCR product was ligated 
into the pETM-11 vector, which adds a TEVpro-cleavable N-terminal 6xHis 
tag (Zou et al., 2003).
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Figure.5..Comparison.of.the.PTB6Raver1.interaction.with.
other.peptide6RRM.complexes. 
A common mode of binding is revealed by superposition of the complex 
of Raver1 PRI3 and PTB RRM2 with the peptide/RRM complexes of 
U2AF65/U2AF35 (PDB – 1jmt), SF3b155/SPF45 (PDB - 2peh) and eIF3j/
eIF3b (PDB – 2krb). PTB RRM2 is coloured tan; other RRMs are grey. 
The superposition was performed for the RRM domains using PyMOL 
(Delano, 2002).
For pull-down experiments we used Quikchange (Stratagene) to mutate 
MS2-Raver1 fusion proteins that were made previously (Rideau et al., 
2006). These incorporate 20-residue Raver1 PRI sequences as N-terminal 
extensions. Plasmids for GST-PTB (Gromak et al., 2003) and GST-nPTB 
— a gift from B.J. Blencowe — (Calarco et al., 2009) have been described. 
All plasmids were sequenced by MWG Eurofins Ltd.
Protein.expression.and.puriTication
PTB proteins were expressed at 37°C in E. coli BL21 (DE3). Cell pellets 
were lysed by sonication in Buffer A (250 mM NaCl, 25 mM Tris, pH 7.8), 
0.1% (v/v) Triton X-100 and 0.5 mM phenylmethanesulfonylfluoride 
containing 1 mg/ml lysozyme. 6xHis tagged proteins were purified from 
clarified lysates using TALON resin (Clontech). Purified proteins eluted in 
Buffer A containing 100 mM imidazole. The 6xHis tag was removed by 
overnight incubation at 4°C with 1 mg of his-tagged TEVpro per 30 mg of 
PRI-RRM2 during dialysis against Buffer A with 5 mM β-mercaptoethanol. 
The cleaved tag and TEVpro were removed in a second round of TALON 
purification. For crystallization, proteins were further purified by gel filtration 
on a Superdex 75 16/60 column (GE Healthcare) in 100 mM NaCl, 25 mM 
Tris (pH 7.8) and 1 mM dithiothreitol (DTT).
For pull-down assays to monitor Raver1 binding, Glutathione S-
transferase (GST) tagged PTB proteins were extracted from E. coli in a 
similar manner and applied a glutathione sepharose 4B column (GE 
Healthcare). The column was washed with Buffer A and proteins eluted in 
Buffer A + 5 mM DTT and 20 mM glutathione (pH 9.0). Purified proteins 
were concentrated by centrifugal filtration to 22 mg/ml, 28 mg/ml, 5.5 mg/ml 
and 4.3 mg/ml for PRI3-RRM2, PRI4-RRM2, GST-PTB and GST-nPTB 
respectively and stored at -80°C.
GST-PTB RRM2 fusion proteins used in Fig. 4 were PCR amplified and 
cloned into the EcoRI site in pGEX3 (to incorporate residues 181-284). 
Cells were lysed by passing twice through a French press in MTPBS buffer 
(150 mM NaCl, 16 mM NaH2PO4, 1 mM DTT, 3 mM PMSF, EDTA-free 
protease cocktail (Roche)). Soluble and insoluble fractions were separated 
by centrifugation at 8,000g for 10min. GST fusion proteins were purified 
through a glutathione sepharose 4B column (GE Healthcare), washed with 
MTPBS+1% Triton X-100, and step-eluted using reduced glutathione. 
Protein containing fractions were dialyzed in buffer E (20mM Hepes, 
100mM KCl, 3mM MgCl2, 0.1mM EDTA, 1mM DTT, 20% glycerol, 0.05% 
NP-40). The GST-PTB and GST-SXL proteins used as control in Fig. 4D 
were prepared as described (Rideau et al, 2006).
Structure.Determination
Purified recombinant PRI-RRM2 proteins at ~18 mg/ml were crystallized by 
sitting drop vapour diffusion using a reservoir solution containing 0.2 M NaI, 
0.1 M Bis-Trispropane (pH 6.5) and 20% polyethylene glycol 3350. Crystals 
were soaked for 1 min in mother liquor with 20% glycerol before flash 
freezing in liquid N2. X-ray diffraction data were collected at beamlines X13 
at DESY, Hamburg, Germany and I02 at Diamond Light Source, Didcot, 
UK. The data were processed with iMosfilm and scaled using SCALA from 
the CCP4 suite (Collaborative Computer Project No. 4, 1994). PRI3-RRM2 
data were phased by molecular replacement in Phaser v1.2 (McCoy et al., 
2007) using the ensemble of NMR structures of PTB RRM2 as a search 
model (Simpson et al., 2004). PRI4-RRM2 was phased by rigid body 
refinement using the RRM2 domain from the refined PRI3-RRM2 structure 
since the two chimeric proteins crystallised isomorphously. Models were 
manually adjusted in O (Jones et al., 1991) and refined with CNS (Brunger 
et al., 1998).
Pull6down.assays
In vitro GST pull-down assays were performed essentially as described in 
(Gromak et al., 2003). Briefly, 35S-Met labelled MS2-Raver1 proteins 
produced by in vitro transcription-translation reactions (TNT quick coupled 
system, Promega) were incubated for 3 hours at 4°C with GST, GST-PTB 
or GST-nPTB in wash buffer (100 mM KCl, 20 mM HEPES (pH 7.9), 
0.5 mM DTT, 0.2% Tween-20 and 10% glycerol) in the presence of 5 µL 
glutathione sepharose 4B. Beads were then washed three times with wash 
buffer and bound protein eluted using SDS loading buffer for SDS-PAGE 
analysis. Protein band intensities on dried gels were recorded using a Fuji 
FLA-5000 phosphor imager; quantitative densitometry was performed using 
AIDA software (Raytest).
Electrophoretic.mobility.shift.assays.(EMSAs)
GST-PTB RRM2 proteins (0.2-3.2 µM) were incubated with 10 fmol of an 
RNA probe spanning the Tpm1 exon 3 polypyrimidine tract which is 
enriched in PTB binding sites (Cherny et al., 2010) in 10mM Hepes, 
100mM KCl, 3mM MgCl2, 5% glycerol, 1mM DTT, 0.25 µg of E. coli rRNA, 
RNase inhibitor (DCP) for 30 min at 30ºC and loaded directly onto a 5% 
polyacrylamide (40:1) gel.
Splicing.assays
Splicing transfection assays were carried out as before (Robinson & Smith, 
2006). Briefly 200 ng of the splicing reporter and 800 ng of effector DNA 
were transfected into HeLa cells in 35mm wells, followed by RT-PCR 
analysis of the splicing products 48 hours after transfection(Robinson and 
Smith, 2006). The splicing reporter pT2Δbp-2MS2 is a modified version of 
TM-2MS2 (Robinson and Smith, 2006) containing a mutation of the 
canonical branch-point of the Tpm1 exon 3, which leads to enhanced exon 
skipping in HeLa cells (Gooding et al., 2006).
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Figure'S1'(related'to'Fig.'1):!Crystallographic!results!for!Raver1!PRIs!bound!to!PTB!RRM2.
Simulated annealing Fo-Fc omit maps of (A) PRI3-RRM2 and (B) PRI4-RRM2, both phased in the absence of a 
model for the PRI peptide. (C) Comparison of molecules A and B from the crystal asymmetric unit of PRI3. 
(D) Comparison of molecules A and B from the crystal asymmetric unit of PRIs 3 and 4 respectively. 
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Figure'S2:!Comparison!of!the!XAray!structure!with!NOEs!measured!in!solution.!
The 11 NOEs observed in the previous NMR study of the RRM2 complex with Raver1 peptide (Rideau et al., 
2006) are shown as dashed lines on the X-ray structure determined here. RRM2 is coloured green, Raver1 
cyan, with key side-chains drawn as sticks. The distances shown are carbon-carbon or carbon-nitrogen and are 
taken from the crystal structure. As the NOEs are between hydrogen atoms, in most cases the distances shown 
greatly overestimate the actual distance measured by NMR. The structure is thus consistent with the NMR 
data, with the exception of the position of Ala 503 on Raver1, which on average is closer in the dynamic 
solution ensemble detected by NMR that was observed in the crystal structure. This discrepancy may be due to 
increased mobility of the bound peptide in the solution structure, as compared to the crystallised complex. 
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Figure'S3'(Related'to'Fig.'3):!PTB!and!PTB!homologues!have!the!same!afFinity!for!PRIs.!
(A) Mapping of sequence differences between PTB and nPTB, ROD1 and smPTB onto the structure of the 
Raver1-PTB complex (PRI3-RRM2). Residues from PTB that are altered in the three paralogues are shown as 
sticks. Y247, which is conserved between the paralogues, is also shown. 
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Figure'S3'(Related'to'Fig.'3;'cont.):!PTB!and!PTB!homologues!have!the!same!afFinity!for!PRIs.!(cont.)
(B) Alignment of RRM2 sequences for PTB paralogues. (C) GST-pulldown of Raver1 PRIs with 2 µg GST or 
6 µg GST-PTB  or GST-nPTB. (D) GST pulldown of Raver1 PRIs 1, 3 and 4 and mutants (PRI3 P6S and PRI4 
L5A/G6P) with 2 µg GST or 6 µg GST-nPTB.
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Figure'S4'(Related'to'Fig.'5):!Superposition!of!the!structure!of!the!PRI3ARRM2!complex!with!the!ICP27/REF!peptideARRM!complex.
The Raver1 peptides (green) bind perpendicular to the helices of PTB RRM2 (tan) inserting two leucines 
(shown as sticks) into a shallow hydrophobic pocket. In contrast, the peptide from ICP27 (blue) binds in an 
orientation that is parallel to dorsal helices in the REF2 RRM (grey) (Tunnicliffe et al., 2011). The ICP27/REF 
complex nevertheless displays some similarity with other peptide/RRM complexes since the ICP27 peptide 
inserts a tryptophan side chain into a hydrophobic pocket between the helices to stabilise the interaction.
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